EMA Committee Backs Higher Dose of Nusinersen for Spinal Muscular Atrophy
Table of Contents
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a higher dose of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA) type 5q, the most common form of the disease.This recommendation, announced by Biogen, the drug’s manufacturer, https://investors.biogen.com/news-releases/news-release-details/european-medicines-agency-chmp-issues-positive-opinion-high-dose, will be forwarded to the European Commission for a final decision. If approved, the higher dosage will be an addition to the currently authorized dosage schedule.
Understanding Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy is a rare, progressive neuromuscular disease that affects motor neurons – nerve cells in the spinal cord crucial for muscle movement. without functional motor neurons, muscles weaken and waste away, leading to difficulties with activities like breathing, swallowing, and walking. SMA is classified based on the age of onset and severity of symptoms. type 5q SMA accounts for approximately 95% of diagnosed cases.https://www.smaeurope.org/about-sma/what-is-sma/
Devote Trial Results Support Higher Dose
The CHMP’s positive opinion is based on data from the DEVOTE clinical trial, a Phase 2/3 study evaluating the efficacy and safety of the enhanced dosage in both previously untreated patients and those already receiving the standard dose of nusinersen. The DEVOTE trial demonstrated statistically meaningful improvements in motor function in both groups. https://www.biogen.com/news/press-release-distribution-details/european-medicines-agency-chmp-issues-positive-opinion-high-dose
nusinersen (Spinraza): A Disease-Modifying Therapy
Nusinersen is an antisense oligonucleotide, a type of drug that alters the production of a specific protein.In SMA, a genetic defect in the SMN1 gene leads to insufficient levels of the SMN protein, which is essential for motor neuron survival. Nusinersen works by modifying the splicing of the SMN2 gene, allowing it to produce more functional SMN protein. It is administered via intrathecal injection (directly into the spinal fluid). https://www.spinraza.com/how-spinraza-works
Addressing Unmet Needs in the SMA Community
“Although great progress has been made in the last decade, there remains an urgency to do more to respond to the still unmet needs of the SMA community,” said Priya Singhal, Executive Vice President and head of Progress at Biogen. “The CHMP’s positive opinion for the high-dose nusinersen regimen represents a promising advancement and is a testament to our commitment to addressing the evolving needs of peopel living with SMA by providing therapies that improve outcomes.” https://investors.biogen.com/news-releases/news-release-details/european-medicines-agency-chmp-issues-positive-opinion-high-dose
What’s Next?
Following the CHMP’s positive opinion, the European Commission will review the recommendation and is expected to make a final decision within approximately three months. If approved, the higher dose of nusinersen will offer a new treatment option for individuals with SMA, potentially improving their motor function and quality of life. Continued research and development are crucial to further advance treatments and address the remaining challenges faced by the SMA community.
Keywords: Spinal Muscular Atrophy, SMA, Nusinersen, Spinraza, EMA, CHMP, Devote Trial, Neuromuscular Disease, Genetic Disorder, Motor Neurons, Antisense Oligonucleotide, Biogen, Drug Approval, Europe, High-Dose Therapy.